outcomes of tp53-mutant aml with venetoclax and decitabine
Published 3 years ago • 652 plays • Length 2:36Download video MP4
Download video MP3
Similar videos
-
1:48
tp53-mutant aml linked to poorer outcomes with decitabine plus venetoclax
-
1:40
outcomes of allohsct in tp53-mutated aml and mds
-
2:26
impact of allelic state on os in tp53-mutant aml and hr-mds
-
1:53
challenges in treating patients with tp53-mutated aml and future outlooks
-
2:24
the challenges of treating tp53-mutated aml and mds
-
1:33
the current guidelines and therapies for tp53-mutated mds and aml
-
12:56
p53 target genes: cell cycle arrest, dna repair, apoptosis
-
11:26
p53 and the response to mitogen overactivity part 2
-
7:43
what are current and emerging aml treatment approaches?
-
1:57
the benefit of allogeneic transplantation in patients with tp53-mutated aml
-
1:36
eprenetapopt plus venetoclax and azacitidine in the treatment of tp53-mutated aml
-
5:16
an analysis of tp53 mutation in aml and hr-mds
-
1:38
the importance of targeting tp53 in aml and agents being explored
-
3:00
apr-246 in tp53 mutated mds and aml
-
1:26
updates in the treatment landscape of p53-mutated aml/mds
-
1:08
novel strategies to target p53-mutant hematological malignancies
-
0:44
unmet needs in aml: tp53 mutations and maintenance therapy
-
8:14
progress in the treatment of tp53 mutated aml
-
1:03
significance of p53 mutations in aml
-
1:27
treatment options for patients with tp53-mutated aml
-
1:20
impact of tp53 mutations on outcomes in myelofibrosis
-
1:57
tolerability and efficacy of magrolimab plus azacitidine in tp53-mutated aml patients